SEATTLE, and VANCOUVER, British Columbia, Sept. 18, 2020 /PRNewswire/ -- Achieve Life
Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical
company committed to the global development and commercialization
of cytisinicline for smoking cessation, today announced data
presented at the Society for Research on Nicotine and Tobacco
European (SRNT-E) Annual Meeting.
The presentation, "Cytisine's Lower Potency at
5-HT3 Receptors May Explain its Lower Incidence of
Nausea and Vomiting than Varenicline", provides a rationale
based on detailed receptor pharmacology to explain why the
incidence of nausea and vomiting associated with cytisinicline
appears to be consistently lower than that seen with
varenicline.
The study, conducted at the University of
Cambridge Department of Biochemistry by Professor
Sarah Lummis and Dr. Kerry Price, was designed to examine the in
vitro binding characteristics of cytisinicline compared to
varenicline at the human 5-HT3 receptor. Using a
radioligand antagonist displacement design, the study reported an
IC50 of 0.50 mM for cytisinicline and 0.25 µM for
varenicline, representing a 2000-greater fold agonist binding
affinity to the 5-HT3 receptor for varenicline compared
to cytisinicline.
"It is well-established that agonist activation of
5-HT3 receptors in the brain stem directly leads to
nausea and vomiting. These data provide further rationale to
explain what has been consistently observed in clinical studies
reporting the adverse event profiles of cytisinicline and
varenicline," commented Achieve's Chief Scientific Officer, Dr.
Anthony Clarke. "Nausea and vomiting
can greatly impact smoker's compliance with medication, their
willingness to complete the course of treatment, and ultimately,
their ability to successfully quit smoking."
Additional safety and efficacy data from the RAUORA head-to-head
non-inferiority trial of cytisinicline vs. varenicline will be
presented later today by Dr. Natalie
Walker at 4:15PM CET. For
additional information please visit
http://ir.achievelifesciences.com/events-and-webcasts.
About Achieve and Cytisinicline
Tobacco use is
currently the leading cause of preventable death and is responsible
for more than eight million deaths annually
worldwide1. It is estimated that 28.7% of
cancer deaths in the U.S. are attributable to cigarette
smoking2. Achieve's focus is to address the
global smoking health and nicotine addiction epidemic through the
development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. It is believed to
aid in smoking cessation by interacting with nicotine receptors in
the brain by reducing the severity of nicotine withdrawal symptoms
and by reducing the reward and satisfaction associated with
smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it
is estimated that over 20 million people have used cytisinicline to
help combat nicotine addiction.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, the timing and nature of
cytisinicline clinical development activities, the potential market
size for cytisinicline and the effectiveness and potential uses and
benefits of cytisinicline. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. Achieve may not actually achieve its plans or product
development goals in a timely manner, if at all, or otherwise carry
out its intentions or meet its expectations or projections
disclosed in these forward-looking statements. These statements are
based on management's current expectations and beliefs and are
subject to a number of risks, uncertainties and assumptions that
could cause actual results to differ materially from those
described in the forward-looking statements, including, among
others, the risk that cytisinicline may not demonstrate the
hypothesized or expected benefits; the risk that cytisinicline may
not be effective in treating a larger breadth of diseases and
addictions; the risk that Achieve may not be able to obtain
additional financing to fund the development of cytisinicline; the
risk that cytisinicline will not receive regulatory approval or be
successfully commercialized; the risk that new developments in the
smoking cessation landscape require changes in business strategy or
clinical development plans; the risk that Achieve's intellectual
property may not be adequately protected; general business and
economic conditions; impacts from the COVID-19 pandemic; and the
other factors described in the risk factors set forth in Achieve's
filings with the Securities and Exchange Commission from time to
time, including Achieve's Annual Reports on Form 10-K and Quarterly
Reports on Form 10-Q. Achieve undertakes no obligation to update
the forward-looking statements contained herein or to reflect
events or circumstances occurring after the date hereof, other than
as may be required by applicable.
Media Contact
Glenn Silver
Glenn.Silver@Finnpartners.com
(646) 871-8485
Investor Relations Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4
Chantix® is a registered trademark of Pfizer Inc.
1 World Health Organization. WHO Report on the
Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017
2 Annals of Epidemiology, Volume 25, Issue 3, 179 -
182.e1
View original content to download
multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-announces-results-from-evaluation-of-cytisinicline-cytisine-versus-chantix-varenicline-in-5-ht3-receptor-binding-assay-study-301133675.html
SOURCE Achieve Life Sciences, Inc.